When was Evolus founded?

Evolus was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Evolus located?

Evolus is headquartered in Irvine, United States.

How many employees does Evolus have?

As of Aug 31, 2026, the latest employee count at Evolus is 406.

Is Evolus a funded company?

Evolus is a funded company, having raised a total of $500K across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 22, 2013.

When was the latest funding round of Evolus?

Evolus' latest funding was a $***** Post IPO round on Apr 25, 2022, with participation from 0 investor.

Where does Evolus rank among its competitors?

Evolus ranks 4th amongst 183 active competitors, of which 44 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Shaperon, which secured $5.82M in Apr, 2026.

Who are the top competitors of Evolus?

Evolus' top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Galderma. Among them, Shaperon secured the most recent funding round in April, 2026.

Evolus - 2026 Company Profile, Funding & Competitors

Company Details

Developer of aesthetic treatments and procedures. The company is focused on the development of self-pay aesthetic products. Its lead product candidate, DWP-450, is an injectable purified botulinum toxin type A complex. This molecule is in Phase II clinical trial for the treatment of moderate-to-severe glabellar lines.

Website: www.evolus.com/
Social
Email ID: *****@evolusinc.com

Key Metrics

Founded Year

2012

Location

Irvine, United States

Stage

Public

Total Funding

$500K in 3 rounds

Latest Funding Round

Post IPO, Apr 25, 2022, $*****

Investors

Daewoong Pharmaceutical & 1 more

Ranked

4^th among 183 active competitors

Employee Count

406 as on Aug 31, 2026

Similar Companies

Revance Therapeutics & 237 more

Exit Details

Public

View Evolus' full profile

Evolus is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EVOLUS, INC. CIN: 216259697 , United States, Active	Aug 17, 2023	-	-	-
Evolus CIN: 40203261177 , Latvia, Active	Sep 22, 2020	€0 - €1M (As on Dec 31, 2024)	2 (As on Dec 31, 2023)	-
EVOLUS, INC. CIN: 1570562 , United States, Active	Nov 08, 2012	$100M - $500M (As on Dec 31, 2025)	273 (As on Dec 31, 2023)	-

Evolus got listed on Feb 08, 2018.

Click here to take a look at Evolus's IPO in detail

Evolus has raised a total funding of $500K over 3 rounds. Its first funding round was on Mar 22, 2013. Evolus has 2 institutional investors.

Here is the list of recent funding rounds of Evolus:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 25, 2022	8429912	Post IPO	1087335	6611330	1333022	4430180
Jul 06, 2020	1677809	Post IPO	7355328	6075330	7808424	Daewoong Pharmaceutical
Mar 22, 2013	7269017	Seed	8264983	5223467	9439428	9369937

Access funding benchmarks and valuations. Sign up today!

View details of Evolus's funding rounds and investors

Evolus' employee count trend

Evolus has 406 employees as of Aug 26. Here is Evolus's employee count trend over the years:

Uncover Evolus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evolus include Revance Therapeutics, Lineage Cell Therapeutics and Galderma. Here is the list of Top 10 competitors of Evolus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
3rd	Galderma 1981, Zug (Switzerland), Public	Manufacturer of products to treat a range of dermatological conditions	-	ADIA, Aisling Capital & 1 others	63/100
4th	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	62/100
5th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
6th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	60/100
7th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
8th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Pontifax, Invesco & 4 others	59/100
9th	Sinclair 1971, London (United Kingdom), Acquired	Manufacturer of injectable and energy-based device treatments for aesthetic purposes	-	Hayfin, Global Emerging Markets	56/100
10th	Shaperon 2008, Seoul (South Korea), Public	Developer of therapies for multiple diseases	-	Samsung Securities, Mirae Asset & 6 others	56/100